To update shareholders on the company’s CPI-300 product and remark on related legal proceedings

IntelGenx Technologies Corp., Annual General Meeting, Oct 05, 2009, at 10:00 US Eastern Time. Location: 6425 Abrams, Ville St-Laurent, Quebec H4S 1X9,Canada. Agenda: To elect four directors to the company's Board of Directors to serve until the next annual meeting of shareholders of the company and until their successors are duly elected and qualified; to ratify the appointment of RSM Richter LLP as the company's independent registered public accountants for the 2009 fiscal year; and to consider and transact such other business as may properly come before the annual meeting and any adjournments thereof .

IntelGenx Technologies Corp. announced that the New Drug Application (NDA) filing for the antidepressant CPI-300, which it developed with Cary Pharmaceuticals had been accepted by the U.S. Food and Drug Administration (FDA) for standard review. CPI-300 is a novel, high strength of Bupropion HCl, the active ingredient in Wellbutrin XL®. As required in connection with the filing of the NDA, IntelGenx’s development partner Cary Pharma, which serves as the NDA applicant, provided notice of the NDA filing to Biovail Laboratories SLR (Biovail) which holds the patent for Wellbutrin XL. In such notice, Cary Pharma contended that CPI-300 would not infringe Biovail’s patents. On August 18, 2009, IntelGenx learned that Cary Pharma was named in a lawsuit filed by Biovail in the U.S. District Court for the District of Delaware for patent infringement under the provisions of the Drug Price Competition and Patent Term Restoration Act of 1984, known as the 'Hatch-Waxman Act,' with respect to Biovail’s U.S. Patent No. 6,096,341. Pursuant to the Hatch-Waxman Act, the filing of the patent infringement lawsuit against Cary Pharma by Biovail instituted an automatic stay of any FDA approval of the NDA until the earlier of a judgment or January 3, 2012.